The levels of C9 and FN1 in non-metastatic and metastatic CRC patient groups, as well as the healthy control group, were determined in WGA-bound plasma fraction and in crude plasma using immunoblot analysis (Figure 5). This evidence concerns the gene C9 and colorectal carcinoma.